GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Piotroski F-Score

VRCDF (Verici Dx) Piotroski F-Score : 5 (As of Mar. 13, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Verici Dx has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Verici Dx's Piotroski F-Score or its related term are showing as below:

VRCDF' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 5

During the past 4 years, the highest Piotroski F-Score of Verici Dx was 5. The lowest was 1. And the median was 3.


Verici Dx Piotroski F-Score Historical Data

The historical data trend for Verici Dx's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Piotroski F-Score Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 1.00 5.00

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Piotroski F-Score Get a 7-Day Free Trial - 1.00 - 5.00 -

Competitive Comparison of Verici Dx's Piotroski F-Score

For the Diagnostics & Research subindustry, Verici Dx's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Verici Dx's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was $-8.73 Mil.
Cash Flow from Operations was $-7.16 Mil.
Revenue was $1.01 Mil.
Gross Profit was $1.01 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (14.305 + 7.443) / 2 = $10.874 Mil.
Total Assets at the begining of this year (Dec22) was $14.31 Mil.
Long-Term Debt & Capital Lease Obligation was $0.38 Mil.
Total Current Assets was $3.99 Mil.
Total Current Liabilities was $3.51 Mil.
Net Income was $-11.41 Mil.

Revenue was $0.00 Mil.
Gross Profit was $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (13.789 + 14.305) / 2 = $14.047 Mil.
Total Assets at the begining of last year (Dec21) was $13.79 Mil.
Long-Term Debt & Capital Lease Obligation was $0.54 Mil.
Total Current Assets was $10.33 Mil.
Total Current Liabilities was $2.25 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Verici Dx's current Net Income (TTM) was -8.73. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Verici Dx's current Cash Flow from Operations (TTM) was -7.16. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-8.734/14.305
=-0.61055575

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-11.407/13.789
=-0.82725361

Verici Dx's return on assets of this year was -0.61055575. Verici Dx's return on assets of last year was -0.82725361. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Verici Dx's current Net Income (TTM) was -8.73. Verici Dx's current Cash Flow from Operations (TTM) was -7.16. ==> -7.16 > -8.73 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.377/10.874
=0.03466985

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.544/14.047
=0.03872713

Verici Dx's gearing of this year was 0.03466985. Verici Dx's gearing of last year was 0.03872713. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=3.989/3.508
=1.13711517

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=10.325/2.252
=4.5848135

Verici Dx's current ratio of this year was 1.13711517. Verici Dx's current ratio of last year was 4.5848135. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Verici Dx's number of shares in issue this year was 170.319. Verici Dx's number of shares in issue last year was 164.668. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.013/1.013
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Verici Dx's gross margin of this year was 1. Verici Dx's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=1.013/14.305
=0.0708144

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/13.789
=0

Verici Dx's asset turnover of this year was 0.0708144. Verici Dx's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Verici Dx has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Verici Dx  (OTCPK:VRCDF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Verici Dx Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Verici Dx's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines